BerGenBio

Report Publication Announcement • Nov 6, 2024

BerGenBio ASA: Invitation to third quarter 2024 results webcast

BerGenBio ASA: Invitation to third quarter 2024 results webcast

Bergen, Norway, 5 November 2024- BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL inhibitors for severe

unmet medical needs, will be announcing its results for the third quarter 2024

on Wednesday 13 November 2024.

BerGenBio's senior management team will provide a business update at 10:00 am

CET. The presentation will webcast live. To participate in the webcast please

use this link:

Webcast Q3

2024 (https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.r

oyalcast.com%2Flandingpage%2Fhegnarmedia%2F20241113_3%2F&data=05%7C02%7Crune.skei

e%40bergenbio.com%7Cad68b1745e94405b232908dce39704c9%7C2b50b422ca6d42af9fc0741b24

8bb071%7C0%7C0%7C638635484987676027%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiL

CJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=gq9418QrexKjJv5W

Ej5zUuBEMYh%2Fr2pTnPw3cS7%2FSB8%3D&reserved=0)

The link to the live webcast will be available at www.bergenbio.com in the

Investors/Financial Reports

section (https://www.bergenbio.com/investors/financial-reports).

The third quarter financial report and presentation will also be made available

on the Company's website in the Investors/Financial Reports

section (https://www.bergenbio.com/investors/financial-reports) from 7:00am CET

the same day.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK.

The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to MAR

article 17 and section 5-12 of the Norwegian Securities Trading Act.